共 132 条
[1]
Kruger S(2019)Advances in cancer immunotherapy 2019–latest trends J Exp Clin Cancer Res 38 268-1813
[2]
Ilmer M(2015)Nivolumab versus everolimus in advanced renal-cell carcinoma New Engl J Med 373 1803-1546
[3]
Kobold S(2019)Five-year survival with combined nivolumab and ipilimumab in advanced melanoma New Engl J Med 381 1535-1830
[4]
Cadilha BL(2019)Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Lancet 393 1819-1867
[5]
Endres S(2016)Nivolumab for recurrent squamous-cell carcinoma of the head and neck New Engl J Med 375 1856-319
[6]
Motzer RJ(2014)PD-1 blockade with nivolumab in relapsed or refractory hodgkin's lymphoma New Engl J Med 372 311-1557
[7]
Escudier B(2020)Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial Lancet 395 1547-11
[8]
McDermott DF(2018)Immune checkpoint inhibitors: recent progress and potential biomarkers Exp Mol Med 50 1-1492
[9]
George S(2015)Releasing the brakes on cancer immunotherapy New Engl J Med 373 1490-1459
[10]
Hammers HJ(2017)Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy J ImmunoTherapy Cancer 5 44-5496